Glenmark Launches Authorized Generic Version of INLYTA in the US
Glenmark expands its US pharmaceutical portfolio with the launch of Axitinib Tablets, targeting a reference product market with annual sales of approximately USD 538.4 million.
Pharma Medicine Launch | 16/11/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy